留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

小鼠心脏移植急性抗体介导的排斥反应模型的建立和分析

廖涛 杨哲 张燕楠 韩飞 孙启全

廖涛, 杨哲, 张燕楠, 等. 小鼠心脏移植急性抗体介导的排斥反应模型的建立和分析[J]. 器官移植, 2020, 11(3): 362-368. doi: 10.3969/j.issn.1674-7445.2020.03.007
引用本文: 廖涛, 杨哲, 张燕楠, 等. 小鼠心脏移植急性抗体介导的排斥反应模型的建立和分析[J]. 器官移植, 2020, 11(3): 362-368. doi: 10.3969/j.issn.1674-7445.2020.03.007
Liao Tao, Yang Zhe, Zhang Yannan, et al. Establishment and analysis of mouse model of acute antibody-mediated rejection in heart transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 362-368. doi: 10.3969/j.issn.1674-7445.2020.03.007
Citation: Liao Tao, Yang Zhe, Zhang Yannan, et al. Establishment and analysis of mouse model of acute antibody-mediated rejection in heart transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 362-368. doi: 10.3969/j.issn.1674-7445.2020.03.007

小鼠心脏移植急性抗体介导的排斥反应模型的建立和分析

doi: 10.3969/j.issn.1674-7445.2020.03.007
基金项目: 

国家自然科学基金 81800663

国家自然科学基金 81770753

广东省基础与应用基础研究基金 2019A1515011942

详细信息
    作者简介:

    廖涛,男,1989年生,硕士,住院医师,研究方向为移植免疫,Email: liaot@mail2.sysu.edu.cn

    通讯作者:

    孙启全,男,1973年生,博士,教授,研究方向为移植免疫,Email: sunqiq@mail.sysu.edu.cn

  • 中图分类号: R617, R392.4

Establishment and analysis of mouse model of acute antibody-mediated rejection in heart transplantation

More Information
  • 摘要:   目的  建立小鼠心脏移植急性抗体介导的排斥反应(AMR)模型并分析其特点。  方法  建立小鼠皮肤移植和心脏移植模型。根据处理方法不同分为同系对照组、非致敏组、预致敏组和预致敏+环孢素组(每组供、受体各9只)。观察各组移植物存活时间、供体特异性抗体(DSA)水平和病理学表现,分析其排斥反应的特点。  结果  同系对照组小鼠心脏移植物在3个月观察期内均长期存活,非致敏组、预致敏组和预致敏+环孢素组心脏移植物存活时间分别为(7.0±0.7)d、(2.6±0.5)d和(5.0±0.7)d,组间比较差异均有统计学意义(均为P < 0.01)。预致敏组在心脏移植术后3 d、预致敏+环孢素组在心脏移植术后5 d DSA水平均较基础值显著升高,差异均有统计学意义(P < 0.05,P < 0.01)。非致敏组病理学表现为心肌细胞破坏,形成间质炎,C4d少量沉积,CD3细胞大量浸润;预致敏组和预致敏+环孢素组病理学表现为心肌细胞破坏,形成毛细血管炎,C4d大量沉积,但是前者CD3细胞浸润多于后者。  结论  利用不同品系间小鼠皮肤移植和心脏移植的基础上加用环孢素可成功建立实用性强的小鼠心脏移植急性AMR模型,为后续AMR的发病机制和干预研究提供基础。

     

  • 图  1  各组受体小鼠心脏移植术后DSA(IgG和IgM)水平

    注:与基础值比较,aP < 0.05,bP < 0.01。

    Figure  1.  Donor specifc antibodies (IgG and IgM) levels after heart transplantation in recipient mice of each group

    图  2  各组受体小鼠心脏移植物的病理学表现(×400)

    Figure  2.  Pathological manifestations of cardiac grafts in recipient mice of each group

  • [1] PATEL JK, KITTLESON M, KOBASHIGAWA JA. Cardiac allograft rejection[J]. Surgeon, 2011, 9(3):160-167. DOI: 10.1016/j.surge.2010.11.023.
    [2] COZZI E, COLPO A, DE SILVESTRO G. The mechanisms of rejection in solid organ transplantation[J]. Transfus Apher Sci, 2017, 56(4):498-505. DOI: 10.1016/j.transci.2017.07.005.
    [3] HUSAIN AN, MIRZA KM, FEDSON SE. Routine C4d immunohistochemistry in cardiac allografts: long-term outcomes[J]. J Heart Lung Transplant, 2017, 36(12):1329-1335. DOI: 10.1016/j.healun.2017.09.004.
    [4] KFOURY AG, HAMMOND ME, SNOW GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection[J]. J Heart Lung Transplant, 2009, 28(8):781-784. DOI: 10.1016/j.healun.2009.04.035.
    [5] LOUPY A, TOQUET C, ROUVIER P, et al. Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection[J]. Am J Transplant, 2016, 16(1):111-120. DOI: 10.1111/ajt.13529.
    [6] PEYSTER EG, MADABHUSHI A, MARGULIES KB. Advanced morphologic analysis for diagnosing allograft rejection: the case of cardiac transplant rejection[J]. Transplantation, 2018, 102(8):1230-1239. DOI: 10.1097/TP.0000000000002189.
    [7] BRAZA MS, VAN LEENT MMT, LAMEIJER M, et al. Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance[J]. Immunity, 2018, 49(5):819-828. DOI: 10.1016/j.immuni. 2018.09.008.
    [8] MAGEE CN, MURAKAMI N, BORGES TJ, et al. Notch-1 inhibition promotes immune regulation in transplantation via regulatory T cell-dependent mechanisms[J]. Circulation, 2019, 140(10):846-863. DOI: 10.1161/CIRCULATIONAHA.119.040563.
    [9] WU C, ZHAO Y, XIAO X, et al. Graft-infiltrating macrophages adopt an M2 phenotype and are inhibited by purinergic receptor P2X7 antagonist in chronic rejection[J]. Am J Transplant, 2016, 16(9):2563-2573. DOI: 10.1111/ajt.13808.
    [10] ZHAO Y, CHEN S, LAN P, et al. Macrophage subpopulations and their impact on chronic allograft rejection versus graft acceptance in a mouse heart transplant model[J]. Am J Transplant, 2018, 18(3):604-616. DOI: 10.1111/ajt.14543.
    [11] ZHANG H, WU J, ZOU D, et al. Ablation of interferon regulatory factor 4 in T cells induces "memory" of transplant tolerance that is irreversible by immune checkpoint blockade[J]. Am J Transplant, 2019, 19(3):884-893. DOI: 10.1111/ajt.15196.
    [12] LIAO T, LIU X, REN J, et al. Noninvasive and quantitative measurement of C4d deposition for the diagnosis of antibody-mediated cardiac allograft rejection[J]. EBioMedicine, 2018, 37:236-245. DOI: 10.1016/j.ebiom. 2018.10.061.
    [13] LIAO T, XUE Y, ZHAO D, et al. In vivo attenuation of antibody-mediated acute renal allograft rejection by ex vivo TGF-β-induced CD4+Foxp3+ regulatory T cells[J]. Front Immunol, 2017, 8:1334. DOI: 10.3389/fimmu.2017.01334.
    [14] ZHAO D, LI S, LIAO T, et al. Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury[J]. Am J Transplant, 2018, 18(5):1083-1095. DOI: 10.1111/ajt.14602.
    [15] ZHAO D, LIAO T, LI S, et al. Mouse model established by early renal transplantation after skin allograft sensitization mimics clinical antibody-mediated rejection[J]. Front Immunol, 2018, 9:1356. DOI: 10.3389/fimmu.2018.01356.
    [16] COHEN D, COLVIN RB, DAHA MR, et al. Pros and cons for C4d as a biomarker[J]. Kidney Int, 2012, 81(7):628-639. DOI: 10.1038/ki.2011.497.
    [17] COLVIN RB, SMITH RN. Antibody-mediatedorgan-allograft rejection[J]. Nat Rev Immunol, 2005, 5(10):807-817. doi: 10.1038/nri1702
    [18] VALENZUELA NM, REED EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies[J]. J Clin Invest, 2017, 127(7):2492-2504. DOI: 10.1172/JCI90597.
    [19] HAAS M. The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts[J]. Am J Transplant, 2018, 18(12):2849-2856. DOI: 10.1111/ajt.15088.
    [20] COLVIN MM, COOK JL, CHANG P, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association[J]. Circulation, 2015, 131(18):1608-1639. DOI: 10.1161/CIR.0000000000000093.
    [21] JORDAN SC, AMMERMAN N, CHOI J, et al. Novel therapeutic approaches to allosensitization and antibody-mediated rejection[J]. Transplantation, 2019, 103(2):262-272. DOI: 10.1097/TP.0000000000002462.
    [22] WU J, ZHANG H, SHI X, et al. Ablation of transcription factor IRF4 promotes transplant acceptance by driving allogenic CD4+ T cell dysfunction[J]. Immunity, 2017, 47(6):1114-1128. DOI: 10.1016/j.immuni.2017.11.003.
    [23] BERRY GJ, BURKE MM, ANDERSEN C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis ofantibody-mediated rejection in heart transplantation[J]. J Heart Lung Transplant, 2013, 32(12):1147-1162. DOI: 10.1016/j.healun.2013.08.011.
    [24] KAMAR N, ALLARD J, ADER JL, et al. Cyclosporine-A-based immunosuppression and renal functional reserve in organ-transplant patients[J]. Transplant Proc, 2004, 36(2 Suppl): 248S-250S. https://www.sciencedirect.com/science/article/abs/pii/S0041134503013514
    [25] LIDDICOAT AM, LAVELLE EC. Modulation of innate immunity by cyclosporine A[J]. Biochem Pharmacol, 2019, 163:472-480. DOI: 10.1016/j.bcp.2019.03.022.
  • 加载中
图(2)
计量
  • 文章访问数:  54
  • HTML全文浏览量:  37
  • PDF下载量:  18
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-02-15
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-05-15

目录

    /

    返回文章
    返回